tbuckley/cabot-search huggingface dataset:
Locally advanced resectable larynx (L) or oropharynx (OP) cancer: Updated results of organ preservation trial ECOG 2399
Authors: A. J. Cmelak, S. Li, B. Murphy, B. Burkey, G. L. Adams, M. Cannon, H. Pinto, D. I. Rosenthal, J. A. Ridge, A. A. Forastiere
Journal: Journal of Clinical Oncology (2006)

5527 Background: Taxane-based concurrent chemoradiation (CCR) for head and neck cancers has proven feasible and has a favorable toxicity profile compared to concurrent cisplatin and radiation. This phase II multi-institutional trial evaluates taxane-based induction chemotherapy followed by CCR for organ preservation in resectable Stage III/IV L and OP patients. Methods: Eligibility: Resectable stage T2N+, or T3-T4N0–3M0 biopsy-proven squamous Ca, age ≥18, PS 0–2, good organ function, and no prior chemotherapy or radiation. Treatment: induction paclitaxel (P) 175 mg/m 2 and carboplatin (C) AUC 6 for 2 cycles q21d followed by concurrent P 30 mg/m 2 q7d with 70 Gy if no evidence of progression. Weekly epoetin alpha 40kU was used if Hgb ≤15 (male) or ≤14 (female). The primary endpoint is organ preservation (freedom from salvage surgery with preserved speech and swallowing). Results: 105/111 pts (69 OP, 36 larynx) were eligible. Median FU is 33 months. No grade 5 toxicities occurred. 94% received full dose RT and 91% received ≥5 cycles of concurrent paclitaxel. At one year post-treatment, 13 (12%) patients required salvage surgery at the primary site (7-L, 6-OP), and 6 pts (6%) progressed and died (3-L, 3-OP). 1 pt (1%) died without progression and 85 pts (81%) are alive without progression (25-L, 60-OP). 12 pts (10%) have developed distant mets (6-L, 6-OP). 1-yr and 2-yr PFS for all pts is 77% and 64%. 12/69 OP and 9/36 L pts have died of disease. 1-yr event-free survival (EFS = no salvage surgery, recurrence or death) is 72% (77%-OP, 64%-L), and 2-yr EFS is 57% (68%-OP, 34%-L) (p = 0.02). 1-yr OS is 93%, 2-yr OS is 74% (OP vs. L p = 0.11). Conclusions: This regimen is well tolerated and is feasible in a multi-institutional setting. EFS with this regimen is lower than expected in larynx patients. The benefit of induction chemotherapy in this setting remains unproven but does not preclude CCR delivery. Funded, in part, by Bristol-Myers Squibb. [Table: see text]
Abstract IA24: Regulation of acute leukemia initiation and progression by long noncoding RNAs.
Authors: Iannis Aifantis
Journal: Clinical Cancer Research (2015)

Abstract Recent efforts to functionally annotate the human genome have revealed that up to 70% of our DNA is transcriptionally active. Since a very small portion of our genome encodes proteins many have hypothesized that a portion of this pervasive transcription results in production of non-coding RNA. By generating high depth RNA-Seq datasets integrated with chromatin features, several labs have revealed the presence of many thousands of previously un-annotated long non-coding RNAs (lncRNA), which are dynamically expressed in response to various stimuli in diverse cellular contexts. Despite these compelling advances, the vast majority of putative lncRNAs have not been proven to be functionally important, although a small portion have clearly been shown to play key regulatory roles. Most importantly, very little is known on the biological role of lncRNAs for human disease and specifically cancer. We provide here, using a combination of deep transcriptome sequencing, high-resolution transcription factor occupancy mapping and chromosome conformation capture data, the first comprehensive identification and characterization of lncRNA expression and function in T-cell acute lymphoblastic leukemia, an aggressive hematologic malignancy affecting both children and adults, driven by oncogenic NOTCH1 mutations and transcriptional activation. Moreover, we provide the first map of oncogene (NOTCH1)-targeted lncRNAs in this disease and identify an individual lncRNA (called LUNAR1) that appears to be essential for tumor growth as it controls cytokine (IGF1) signaling. Indeed, we were able to show that the LUNAR1 locus loops on a novel IGF1R enhancer controlling the expression of this important cytokine receptor. These studies suggest that: a) lncRNAs could be used as both biomarkers and therapy targets in human cancer, b) more efficient methods for large-scale inference and validation of lncRNA function are needed to fully understand their biological significance and, c) LUNAR1 is one of the first lncRNAs that can control growth of acute leukemia and a potential therapeutic target. These points will be addressed in this presentation. Citation Format: Iannis Aifantis. Regulation of acute leukemia initiation and progression by long noncoding RNAs. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr IA24.
Comparison of Polymerized and Unpolymerized Antigen E for Immunotherapy of Ragweed Allergy
Authors: W. James Metzger, Roy Patterson, C. Raymond Zeiss, John S. Irons, Jacob J. Pruzansky, Irena M. Suszko, Doris Levitz
Journal: New England Journal of Medicine (1976)

Polymerization of ragweed antigen into high-molecular-weight polymers could improve immunotherapy for ragweed pollinosis by reducing side effects while retaining immunogenicity. To study this thesis, 23 ragweed-sensitive patients were treated with either ordinary ragweed antigen E or ragweed antingen E polymerized by glutaraldehyde. Four patients received the polymerized antigen, and six controls ordinary antigen according to the standard immunotherapy schedule; two groups of three patients received either form by a "doubling-dose" schedule. Seven subjects received the polymerized antigen by a schedule in which each successive dose was tripled. Serum antigen E binding capacity (blocking antibody) increased significantly in all subjects (P less than 0.001 by Student-test). Patients treated with polymerized antigen had fewer local and generalized reactions than those receiving the monomeric preparation. Polymerized ragweed antigen permits more rapid immunization of atopic persons, with fewer side effects than standard monomeric preparations.
The Value of the Thoracoabdominal Incision in the Removal of Kidney Tumors
Authors: Richard Chute, Lamar Soutter, Walter S. Kerr
Journal: New England Journal of Medicine (1949)

ALTHOUGH the kidneys are situated below the diaphragm, they lie to a large extent within the thorax, sheltered by the lower ribs. Chiefly because the unyielding bony thoracic cage frequently bars the way to a free and satisfactory surgical exposure of the upper portion of the kidneys when they are enlarged, the lumbar extraperitoneal incision commonly used for renal surgery, with or without removal of the twelfth rib, and also the transperitoneal approach often leave a great deal to be desired in the way of exposure when one is dealing with large tumors of the kidney. While searching for an . . .
Treatment of Parkinson's Disease with Bromocriptine
Authors: Abraham Lieberman, Mark Kupersmith, Eli Estey, Menek Goldstein
Journal: New England Journal of Medicine (1976)

Bromocriptine in high doses (up to 100 mg per day) was administered to 14 patients with advanced Parkinson's disease whose disorder was progressing despite optimum treatment with levodopa combined with a peripheral dopa decarboxylase inhibitor (carbidopa). In 10, bromocriptine (mean dose, 57 mg) induced a statistically significant (P<0.01) improvement in rigidity, tremor, bradykinesia, gait disturbance and total score. In seven patients levodopa with carbidopa was completely replaced by bromocriptine (mean dose, 70 mg), with improvement in four. Adverse effects were similar to those observed with levodopa and carbidopa, except that in individual patients abnormal involuntary movements and diurnal oscillations in performance (on-off effect) were decreased whereas orthostatic hypotension and mental changes were increased. Bromocriptine appears to be a major new agent in Parkinson's disease that is especially promising in patients no longer responding to levodopa. (N Engl J Med 295:1400–1404, 1976)
Endpiece: What's in a name
Authors: Helen Mary Worthington
Journal: BMJ (2006)

Language is as vital to the physician's art as the stethoscope or the scalpel. A doctor begins by examining the words of his patient to determine their clinical significance. He then translates the words into medical language, describing how the condition came to be, what it means, and how it may evolve. Of all the words the doctor uses, the name he gives the illness has the greatest weight. It forms the foundation of all subsequent discussion, not only between doctor and patient but also between doctor and doctor and between patient and patient.

Groopman J. Hurting all over. New Yorker 2000 Nov 13;76(34):78-92
Management of Community-Acquired Pneumonia
Authors: Cornelis H. van Werkhoven, Jan Jelrik Oosterheert, Marc J. M. Bonten
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gene disruption of dematin causes precipitous loss of erythrocyte membrane stability and severe hemolytic anemia
Authors: Yunzhe Lu, Toshihiko Hanada, Yuko Fujiwara, Jennifer O. Nwankwo, Adam J. Wieschhaus, John Hartwig, Sha Huang, Jongyoon Han, Athar H. Chishti
Journal: Blood (2016)
Case 47-1993
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Ferdinand J. Venditti, John T. Fallon
Journal: New England Journal of Medicine (1993)

Presentation of CaseA 28-year-old man was admitted to the hospital because of recurrent ventricular tachycardia.There was a 12-year history of chronic active hepatitis with cirrhosis for which the patient took prednisone daily. Nine years before entry ulcerative colitis developed, with frequent exacerbations, especially during the spring. Four years later eosinophilia was detected; it ranged from 10 to 20 percent on differential counts and decreased during intervals when increased doses of prednisone were given. Anosmia and alopecia universalis developed, with apparent improvement when doses of prednisone were higher.Fifty-eight months before entry third-degree atrioventricular block occurred, and a subcutaneous . . .
S78 Electronic cigarette advertising impacts adversely on smoking behaviour within a London student cohort: a cross-sectional survey
Authors: C Ratneswaran, R Judge, M Colquhoun, J Steier, TK Khong
Journal: Thorax (2015)

<h3>Introduction</h3> In contrast to tobacco smoking, electronic cigarette (“vaping”) advertisement has been approved in the UK since January 2013. Currently, there are 2.6 million e-cigarette users in the UK. The impact of e-cigarette advertisement on tobacco use has not been studied in detail. We hypothesised that e-cigarette advertisement impacts on smoking behaviour. <h3>Methods</h3> A structured survey was constructed to assess the impact of e-cigarette advertising on the perceived social acceptability of cigarette smoking; and, on trying both cigarettes and e-cigarettes (on a scale of 1 to 5/‘not at all’ to ‘a great deal’). The survey was administered between January to March 2015 to London university students, before and after viewing 5 UK adverts including a TV commercial. <h3>Results</h3> Data were collected from 106 participants (22 ± 2 years, 66%male), comprising 34 current cigarette-smokers, 57 non-smokers and 15 ex-smokers. There were 17 vapers, 82 non-vapers and 7 ex-vapers. After viewing the adverts, both smokers (2.6 ± 1.0 vs 3.8 ± 1.1, p = 0.0002) and non-smokers (3.2 ± 0.7 vs 3.7 ± 0.8, p = 0.004) felt e-cigarette advertising increased the social acceptability of smoking; and, both smokers and non-smokers were more likely to try e-cigarettes (3.6 ± 1.0 and 2.6 ± 1.0 respectively, p &lt; 0.0001) as well as conventional cigarettes (3.4 ± 1.0 and 1.5 ± 0.9 respectively, p &lt; 0.0001). Additionally after viewing, vapers felt e-cigarettes were ‘less effective’ at helping people stop smoking compared to before (3.6 ± 0.<i>7 </i>vs 4.0 ± 0.6, p = 0.004). <h3>Conclusion</h3> E-cigarette advertising encourages e-cigarette <i>and</i> conventional cigarette use in young smokers and non-smokers. The adverts impact on the social acceptability of smoking without regarding the importance of smoking cessation.
Association Between Asthma Control Test, Peripheral Eosinophil Counts, and Serum Total Immunoglobulin E Levels in Severe Asthmatics
Authors: Santiago Alvarez Arango, Jennifer Toh, Denisa Ferastraoaru, Gabriele de Vos, David L. Rosenstreich, Sunit P. Jariwala
Journal: Journal of Allergy and Clinical Immunology (2016)
A Comparison of Budesonide and Mesalamine for Active Crohn's Disease
Authors: O O Thomsen, A Cortot, D Jewell, J P Wright, T Winter, F T Veloso, M Vatn, T Persson, E Pettersson
Journal: New England Journal of Medicine (1998)

Crohn's disease is often treated with glucocorticoids or mesalamine. We compared the efficacy and safety of controlled-ileal-release budesonide capsules and slow-release mesalamine tablets in patients with active Crohn's disease affecting the ileum, the ascending colon, or both.
Prevalence of Endogenous Type-C Virus in Normal Hamster Tissues and Hamster Tumors Induced by Chemical Carcinogens, Simian Virus 40, and Polyoma Virus 2
Authors: Aaron E. Freeman, Gary J. Kelloff, Mina Lee Vernon, William T. Lane, Worth I. Capps, Sandra D. Bumgarner, Horace C. Turner, Robert J. Huebner
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Prevalence of Endogenous Type-C Virus in Normal Hamster Tissues and Hamster Tumors Induced by Chemical Carcinogens, Simian Virus 40, and Polyoma Virus Get access Aaron E. Freeman, Aaron E. Freeman 3The Children's Hospital of Akron, Akron, Ohio 44308 Search for other works by this author on: Oxford Academic PubMed Google Scholar Gary J. Kelloff, Gary J. Kelloff 4Viral Carcinogenesis Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Mina Lee Vernon, Mina Lee Vernon 5Microbiological Associates, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar William T. Lane, William T. Lane 4Viral Carcinogenesis Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Worth I. Capps, Worth I. Capps 4Viral Carcinogenesis Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Sandra D. Bumgarner, Sandra D. Bumgarner 5Microbiological Associates, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Horace C. Turner, Horace C. Turner 4Viral Carcinogenesis Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert J. Huebner Robert J. Huebner 4Viral Carcinogenesis Branch, National Cancer Institute, National Institutes of Health, U.S. Department of Health, Education, and Welfare, Bethesda, Md. 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 5, May 1974, Pages 1469–1476, https://doi.org/10.1093/jnci/52.5.1469 Published: 01 May 1974 Article history Received: 03 April 1973 Revision received: 19 December 1973 Accepted: 25 January 1974 Published: 01 May 1974
A Point Mutation in the SH2 Domain of Bruton's Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia
Authors: Douglas C. Saffran, Ornella Parolini, Marjorie E. Fitch-Hilgenberg, David J. Rawlings, Daniel Afar, Owen N. Witte, Mary Ellen Conley
Journal: New England Journal of Medicine (1994)

X-Linked Agammaglobulinemia is the prototypical humoral immunodeficiency first described by Bruton in 19521. It is characterized by a paucity of circulating B cells and a drastic reduction in the serum concentrations of immunoglobulins2,3. Studies analyzing patterns of X chromosome inactivation showed that the genetic defect was intrinsic to the B-cell lineage,4 and mapping studies located the defect in the midportion of the long arm of the X chromosome at Xq225–7. Recently, two reports demonstrated that mutations of the cytoplasmic tyrosine kinase gene Btk (the gene for Bruton's tyrosine kinase, previously designated bpk or atk) are . . .
Docetaxel and carboplatin combination chemotherapy in advanced or recurrent cervix cancer of the uterus. A pilot study
Authors: S. Nagao, K. Fujiwara, T. Oda, H. Ishikawa, H. Koike, H. Tanaka, I. Kohno
Journal: Journal of Clinical Oncology (2004)

5099 Background: This is a pilot study to assess an efficacy and safety of combination chemotherapy of docetaxel and carboplatin in advanced or recurrent uterine cervix cancer for the future trial. Methods:The patients eligible for this study were those who were histologically confirmed (squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma), advanced (stage IB2-IV) or recurrent uterine cervix cancer.The patient must have measurable lesion and must have sufficient bone marrow, renal, and liver function. Docetaxel was administered intravenously (IV) at 60 mg/m2 followed by IV carboplatin administration at AUC=6. Chemotherapy was repeated 1–6 courses depending on the purpose of the therapy. The response was evaluated based on RECIST criteria. However, confirmation of the objective response no less than 4 weeks after criteria for response are first met was not required in patients who underwent chemotherapy as a neoadjuvant setting. In these patients surgery was performed as soon as sufficient response was obtained and recovered from toxicities. Toxicity grade was determined by NCI-CTC version 2. Results: During January 2001 and April 2003, 13 patients were entered in this study. Distribution of stage was IB2; 1, IIB; 6, IIIB; 2, IVB; 2, Recurrent; 2. There were 6 squamous cell carcinomas, 5 adenocarcinomas and 1 adenosquamous cell carcinoma. Overall response rate was 84.6% (1 CR, 10 PR, and 2 SD). No progression of disease was observed. All 5 adenocarcinoma patients under neoadjuvant chemotherapy setting responded including 1 pathological CR. Incidences of grade 3/4 toxicities were 48.6% for leukocytopenia, 71.4% for neutrocytopenia, .and 11.8% for thrombocytopenia. No grade 3/4 neurotoxicity was observed. Conclusions: Combination of docetaxel and carboplatin is effective and safe treatment for uterine cervix cancer. Further evaluation particularly targeted on cervical adenocarcinoma is warranted. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
Studies of Testosterone Metabolism in a Patient with Masculinization Due to Stromal Hyperthecosis
Authors: C. Wayne Bardin, Mortimer B. Lipsett, John H. Edgcomb, John R. Marshall
Journal: New England Journal of Medicine (1967)

THE occurrence of masculinization in the adult woman generally implies the presence of an ovarian or adrenal tumor. There are, however, rare reports of masculinization associated with such entities as polycystic ovary, hyperthecosis and hilarcell hyperplasia. In none of these cases has androgen production been studied intensively. The case reported below concerns a patient with virilization and hyperthecosis (thecomatosis, thecosis or diffuse luteinization of the ovarian stroma) of the ovaries. Measurement of ovarian and peripheral venous testosterone levels showed that the ovaries were secreting testosterone in quantities sufficient to account for the virilization.MethodsThe following routine methods were used: . . .
Cellular and Molecular Mechanisms of AKI
Authors: Anupam Agarwal, Zheng Dong, Raymond Harris, Patrick Murray, Samir M. Parikh, Mitchell H. Rosner, John A. Kellum, Claudio Ronco
Journal: Journal of the American Society of Nephrology (2016)

In this article, we review the current evidence for the cellular and molecular mechanisms of AKI, focusing on epithelial cell pathobiology and related cell-cell interactions, using ischemic AKI as a model. Highlighted are the clinical relevance of cellular and molecular targets that have been investigated in experimental models of ischemic AKI and how such models might be improved to optimize translation into successful clinical trials. In particular, development of more context-specific animal models with greater relevance to human AKI is urgently needed. Comorbidities that could alter patient susceptibility to AKI, such as underlying diabetes, aging, obesity, cancer, and CKD, should also be considered in developing these models. Finally, harmonization between academia and industry for more clinically relevant preclinical testing of potential therapeutic targets and better translational clinical trial design is also needed to achieve the goal of developing effective interventions for AKI.
Incidence, Latency, and Morphologic Types of Neoplasms Induced by Simian Virus 40 Inoculated Intravenously Into Hamsters of Three Inbred Strains and One Outbred Stock2
Authors: George T. Diamandopoulos
Journal: JNCI Journal of the National Cancer Institute (1978)

The incidence, latency, and morphologic types of neoplasms induced in hamsters of the three inbred strains LSH/-SsLak, LHC/Lak, and MHA/SsLak, inoculated iv at 3 weeks of age with 107.5 median tissue culture infective dose (TCID50) of simian virus 40 (SV40), were determined and compared with those of the outbred stock LVG/Lak. Although the incidence and latency were approximately the same in hamsters of the three inbred strains, hamsters of the outbred stock exhibited almost complete resistance to tumor induction under identical experimental conditions. The morphologic types of neoplasms, i.e., lymphocytic leukemia, reticulum cell sarcoma, osteogenic sarcoma, and anaplastic sarcoma, induced in inbred hamsters were similar to those induced in outbred hamsters inoculated iv with 108.5 TCID50 SV40. The lymphocytic leukemias that developed in the 2 LSH/SsLak ibred hamsters were established as tumor transplants in vivo and as permanent cell lines in vitro.
Prevalence of cardiovascular risk factors in rural and urban Puriscal
Authors: Hannia Campos Núñez, Leonardo Mata Jiménez, Xinia Siles Díaz, Marcela Vives Blanco, José M. Ordovas, Ernst J. Schaefer
Journal: Circulation (1992)

Articulo cientifico -- Universidad de Costa Rica. Instituto de Investigaciones en Salud, 1992. Debido a las politicas de la revista en la que el articulo fue publicado no es posible distribuir la version del editor/PDF.